Monthly archives: October 2021

2 posts

Immunology is on the rise in pharmaceutical trends

In 2014, the government led by Juha Sipilä presented the growth strategy for the Finnish healthcare sector.  This was a recognition of a sector that has invested significantly in health research and has risen to the absolute top of health research in many sectors globally. Finland offers a tremendous functioning ecosystem for medical research.

Now, in 2021, we already have a third government that has continued to commit to this strategy, at the very least.  However, the recent uproar over funding cuts in science did not increase confidence in the current government’s desire to improve public funding for biomedical research in Finland. The key pillars of the growth strategy include the National Cancer Centre, the Genome Center and the Finnish Biobank Cooperative FINBB. They are still waiting for the necessary government start-up grants. Despite the lack of promised government aid, projects have progressed, although no decision has yet been taken, for example, on the funding of a national drug development centre.

Continue reading

Wins and losses – Does a failed drug development project matter?

Developing a drug from an idea to a finished product is a long journey. It takes easily more than ten years and can cost hundreds of millions of euros. However, the end result may be a drug that relieves symptoms or heals the patient. Sometimes we manage to also prevent diseases.

And for this reason, the failure of a drug development project affects many. Researchers who have done basic and applied research are disappointed, start-ups are facing financial difficulties, stock prices of large pharmaceutical companies are falling, doctors are not getting new tools, and patients who want the medicine are disappointed. Members of my own profession will be left without work, sitting by their Excel sheets. There is no need for cost-benefit calculations by health economists.

Continue reading